Brief: Biomerieux H1 Organic Sales Growth EUR 1.97 Bln, Adjusts Mid-Term Guidance
BRIEF-Biomerieux H1 Organic Sales Growth EUR 1.97 Bln, Adjusts Mid-Term Guidance July 28 (Reuters) - Biomerieux SA BIOX.PA:
0.2% ORGANIC SALES GROWTH IN H1 26, AT EUR 1,965 MILLION
Q2 2026 SALES TOTALED EUR 981 MILLION, WITH SOLID ORGANIC GROWTH AT +5%,
H1 CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEM (CEBIT) AT €313 MILLION
H1 NET INCOME (GROUP SHARE) AMOUNTED TO EUR 226 MILLION, UP 41% COMPARED TO H1 2025
H1 ADJUSTED EPS OF €1.99
FREE CASH-FLOW GENERATION UP 76% IN H1 2026 VERSUS H1 2025
BIOMÉRIEUX CONFIRMS ITS 2026 GUIDANCE
BIOMÉRIEUX IS ADJUSTING ITS MIDTERM FINANCIAL OUTLOOK.
FOR 2027 AND 2028, BIOMÉRIEUX IS AIMING AT DELIVERING +3% TO +6% ORGANIC ANNUAL SALES GROWTH (VERSUS “7% CAGR 2024/2028” PREVIOUSLY)
FOR 2027 AND 2028, BIOMÉRIEUX IS AIMING AT DELIVERING ORGANIC ANNUAL CEBIT GROWTH HIGHER THAN ORGANIC SALES GROWTH (VERSUS "AT LEAST +10%" PREVIOUSLY)
Source text: [here]
Further company coverage: BIOX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;;))
Recent news on Biomerieux SA
See all newsBrief: Biomerieux Receives US FDA 510(K) Clearance And Ivdr CE Marking For Vitek Pro
Brief: bioMerieux Receives FDA Clearance For Latest Versions Of Biofire® Filmarray
Europe Research Roundup: Asos, Erste Group, SCHOTT pharma
Europe Research Roundup: Acceler8 Ventures, Hermes, Soitec
BioMerieux shares rise after Q3 sales beat